BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2045930)

  • 1. Measurement of receptor concentration and forward-binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin.
    Vera DR; Stadalnik RC; Trudeau WL; Scheibe PO; Krohn KA
    J Nucl Med; 1991 Jun; 32(6):1169-76. PubMed ID: 2045930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of in vivo receptor measurements via in vitro radioassay: technetium-99m-galactosyl-neoglycoalbumin as prototype model.
    Kudo M; Vera DR; Trudeau WL; Stadalnik RC
    J Nucl Med; 1991 Jun; 32(6):1177-82. PubMed ID: 2045931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding.
    Vera DR; Krohn KA; Stadalnik RC; Scheibe PO
    J Nucl Med; 1984 Jul; 25(7):779-87. PubMed ID: 6737077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A perspective: in vivo assay of receptor-ligand binding.
    Spencer RP
    J Nucl Med; 1991 Jun; 32(6):1182-3. PubMed ID: 2045932
    [No Abstract]   [Full Text] [Related]  

  • 5. Local identifiability of a receptor-binding radiopharmacokinetic system having measured parameters of known uncertainty.
    Vera DR; Scheibe PO; Banin Y; Stadalnik RC
    IEEE Trans Biomed Eng; 1994 Sep; 41(9):891-7. PubMed ID: 7959816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic sensitivity of a receptor-binding radiopharmaceutical: technetium-99m galactosyl-neoglycoalbumin.
    Vera DR; Woodle ES; Stadalnik RC
    J Nucl Med; 1989 Sep; 30(9):1519-30. PubMed ID: 2549225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goodness-of-fit and local identifiability of a receptor-binding radiopharmacokinetic system.
    Vera DR; Scheibe PO; Krohn KA; Trudeau WL; Stadalnik RC
    IEEE Trans Biomed Eng; 1992 Apr; 39(4):356-67. PubMed ID: 1592401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic uptake of [99mTc]galactosyl-neoglycoalbumin is sensitive to receptor quantity.
    Kudo M; Vera DR; Trudeau WL; Stadalnik RC
    Int J Rad Appl Instrum B; 1991; 18(7):663-6. PubMed ID: 1787074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tc-99m-galactosyl-neoglycoalbumin: in vivo characterization of receptor-mediated binding to hepatocytes.
    Vera DR; Krohn KA; Stadalnik RC; Scheibe PO
    Radiology; 1984 Apr; 151(1):191-6. PubMed ID: 6701314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of a receptor-binding radiopharmacokinetic model.
    Vera DR; Stadalnik RC; Metz CE; Pimstone NR
    J Nucl Med; 1996 Jan; 37(1):160-4. PubMed ID: 8543988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Galactosyl neoglycoalbumin:preparation and studies of its binding with hepatic special receptor].
    Pang Q; Yang L; Zhong Y; Guan C; Zhao Q; Tan T
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Sep; 22(4):368-71. PubMed ID: 1814813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.
    Virgolini I; Angelberger P; Müller C; O'Grady J; Sinzinger H
    Br J Clin Pharmacol; 1990 Feb; 29(2):207-14. PubMed ID: 2306412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of human hepatic binding protein (HBP) via 99mTc-galactosyl-neoglycoalbumin (NGA) liver scintigraphy.
    Virgolini I; Müller C; Angelberger P; Höbart J; Bergmann H; Sinzinger H
    Wien Klin Wochenschr; 1991; 103(15):458-61. PubMed ID: 1926872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional liver imaging with 99Tcm-galactosyl-neoglycoalbumin (NGA) in alcoholic liver cirrhosis and liver fibrosis.
    Virgolini I; Müller C; Angelberger P; Höbart J; Bergmann H; Sinzinger H
    Nucl Med Commun; 1991 Jun; 12(6):507-17. PubMed ID: 1866104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies.
    Vera DR; Stadalnik RC; Krohn KA
    J Nucl Med; 1985 Oct; 26(10):1157-67. PubMed ID: 4045560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.
    Virgolini I; Müller C; Klepetko W; Angelberger P; Bergmann H; O'Grady J; Sinzinger H
    Br J Cancer; 1990 Jun; 61(6):937-41. PubMed ID: 2164838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technetium-99m NGA functional hepatic imaging: preliminary clinical experience.
    Stadalnik RC; Vera DR; Woodle ES; Trudeau WL; Porter BA; Ward RE; Krohn KA; O'Grady LF
    J Nucl Med; 1985 Nov; 26(11):1233-42. PubMed ID: 2997417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of functioning hepatocyte mass via [99mTc]galactosyl-neoglycoalbumin.
    Kudo M; Vera DR; Stadalnik RC; Esquivel CO; Trudeau WL; Ikekubo K; Todo A
    Dig Dis Sci; 1993 Dec; 38(12):2183-8. PubMed ID: 8261818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: a radiopharmaceutical for regional measurement of hepatic receptor biochemistry.
    Vera DR
    J Nucl Med; 1992 Jun; 33(6):1160-6. PubMed ID: 1597732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tc-NGA imaging in liver transplantation: preclinical studies.
    Woodle ES; Vera DR; Stadalnik RC; Ward RE
    Surgery; 1987 Jul; 102(1):55-62. PubMed ID: 3296267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.